# Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

> **NCT04419558** · PHASE3 · TERMINATED · sponsor: **Kyntra Bio** · enrollment: 372 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** Pamrevlumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04419558
- **Lead sponsor:** Kyntra Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-30
- **Primary completion:** 2023-09-04
- **Final completion:** 2023-09-04
- **Target enrollment:** 372 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2024-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04419558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04419558, "Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04419558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*